Cellular Immunotherapy for Carcinoma Using Genetically Modified EGFR-Specific T Lymphocytes

• DOI: 10.1593/neo.13168
• Publication Date: 2015-04-23T13:07:09Z
• Authors: Xikun Zhou; Jing Li; Zhen Wang; Zhongwen Chen; Ji Qiu; Yinbing Zhang; Wei Wang; Yu Ma; Nongyu Huang; Kaijun Cui; Jiong Li; Yu-quan Wei
• Keywords: Targeted Therapy

Epidermal growth factor receptor (EGFR) is overexpressed in a variety of human malignancies, including pancreatic cancer, breast colon and non-small cell lung cancer. Overexpression EGFR predictive marker therapeutic response several lines evidence suggest that an excellent target for tumor therapy. However, the effective antitumor capacity EGFR-specific T cells against EGFR-overexpressing has not been fully elucidated. In our previous study, we identified anti-EGFR single-chain variable fragment (scFv) with specific high affinity after screening by ribosome display. this anticancer potential scFv was investigated on basis cell-targeted A chimeric antigen (CAR) targeting constructed expressed membrane lymphocytes. These CAR-modified demonstrated efficacy both vitro vivo. addition, safety evaluation showed lymphocytes have no or very minimal acute systemic toxicity. Taken together, study provided experimental clinical application genetically engineered lymphocytes; moreover, also evaluate new interesting therapy protocol.